Literature DB >> 20927593

Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital.

Kenneth Kar-Lung Yan1, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Henry Lik-Yuen Chan.   

Abstract

BACKGROUND: Contraindications to interferon and ribavirin for treatment of chronic hepatitis C (CHC) are well recognized, and previous data indicated the consequent suboptimal treatment uptake. AIM: To evaluate the treatment rate of CHC patients in a tertiary referral center in Hong Kong, and to examine the reasons for non-treatment.
METHODS: A retrospective review of all referred CHC patients to the outpatient clinic was conducted. Treatment uptake rate was evaluated and patients' sociodemographic, biochemical, and histological data were examined to identify reasons for treatment decision.
RESULTS: CHC patients (303) were assessed for antiviral therapy from 2000 to 2009. Of the patients, 138 (45.5%) did not receive antiviral therapy. Reasons for non-treatment were as follows: 31.9% declined treatment, 18.8% had decompensated cirrhosis, 12.3% were considered too elderly, 17.4% had too mild liver disease, 7.2% had psychiatric history, 7.2% had significant comorbidities, and 2.9% had ongoing alcohol or substance abuse. Independent factors associated with non-treatment were older age (adjusted odds ratio [aOR] 1.05, 95% confidence interval [CI] 1.03-1.08, p < 0.001), significant comorbidities (aOR 2.53, 95% CI 1.34-4.78, p = 0.004), psychiatric history (aOR 6.04, 95% CI 2.14-17.02, p < 0.001), mild liver disease (aOR 7.72, 95% CI 3.86-15.44, p < 0.001) and decompensated cirrhosis (aOR 9.42, 95% CI 2.57-34.50, p < 0.001).
CONCLUSIONS: Current treatment uptake for CHC patients was suboptimal, as a large proportion of patients were either reluctant for treatment or not suitable for the current antiviral therapy. Multidisciplinary interventions are needed in the short term while alternative antiviral therapy is desired in the long term to overcome barriers to treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20927593     DOI: 10.1007/s10620-010-1412-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

1.  Viral hepatitis C in Hong Kong.

Authors:  Nancy Leung; Carol Chu; John S Tam
Journal:  Intervirology       Date:  2006       Impact factor: 1.763

2.  Efficacy of interferon therapy in elderly patients with chronic hepatitis C.

Authors:  Rikako Koyama; Yasuji Arase; Kenji Ikeda; Fumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Saitoh; Masahiro Kobayashi; Norio Akuta; Takashi Someya; Tetsuya Hosaka; Hitomi Sezaki; Mariko Kobayashi; Hiromitsu Kumada
Journal:  Intervirology       Date:  2006       Impact factor: 1.763

3.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

4.  Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.

Authors:  Sarah L George; Bruce R Bacon; Elizabeth M Brunt; Kusal L Mihindukulasuriya; Joyce Hoffmann; Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

5.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

6.  Treatment responses in Asians and Caucasians with chronic hepatitis C infection.

Authors:  Kenneth-K Yan; Marianne Guirgis; Thuy Dinh; Jacob George; Anouk Dev; Alice Lee; Amany Zekry
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

7.  Changing trends in hepatitis C-related mortality in the United States, 1995-2004.

Authors:  Matthew Wise; Stephanie Bialek; Lyn Finelli; Beth P Bell; Frank Sorvillo
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

8.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

9.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

10.  Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.

Authors:  Chung-Feng Huang; Jeng-Fu Yang; Chia-Yen Dai; Jee-Fu Huang; Nai-Jen Hou; Ming-Yen Hsieh; Zu-Yau Lin; Shinn-Cherng Chen; Ming-Yuh Hsieh; Liang-Yen Wang; Wen-Yu Chang; Wan-Long Chuang; Ming-Lung Yu
Journal:  J Infect Dis       Date:  2010-03       Impact factor: 5.226

View more
  3 in total

1.  Treatment uptake of patients with chronic hepatitis C: can we expect and do more?

Authors:  Chia-Yen Dai
Journal:  Dig Dis Sci       Date:  2010-12       Impact factor: 3.199

Review 2.  Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis.

Authors:  Philip Vutien; Michelle Jin; Michael H Le; Pauline Nguyen; Sam Trinh; Jee-Fu Huang; Ming-Lung Yu; Wan-Long Chuang; Mindie H Nguyen
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

3.  Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience.

Authors:  Peter Nguyen; Philip Vutien; Joseph Hoang; Sam Trinh; An Le; Lee Ann Yasukawa; Susan Weber; Linda Henry; Mindie H Nguyen
Journal:  BMJ Open Gastroenterol       Date:  2017-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.